Aberdeen Group’s Gilead Sciences GILD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $153M | Sell |
1,100,253
-85,423
| -7% | -$12M | 0.25% | 79 |
|
|
2025
Q4 | $146M | Sell |
1,185,676
-162,368
| -12% | -$19.7M | 0.23% | 82 |
|
|
2025
Q3 | $152M | Sell |
1,348,044
-160,874
| -11% | -$18.3M | 0.24% | 78 |
|
|
2025
Q2 | $167M | Sell |
1,508,918
-425,079
| -22% | -$45.2M | 0.28% | 69 |
|
|
2025
Q1 | $216M | Sell |
1,933,997
-1,833,958
| -49% | -$189M | 0.42% | 40 |
|
|
2024
Q4 | $346M | Sell |
3,767,955
-260,606
| -6% | -$23.5M | 0.65% | 22 |
|
|
2024
Q3 | $336M | Sell |
4,028,561
-113,485
| -3% | -$8.66M | 0.62% | 25 |
|
|
2024
Q2 | $284M | Buy |
4,142,046
+199,779
| +5% | +$13.3M | 0.54% | 30 |
|
|
2024
Q1 | $289M | Buy |
3,942,267
+178,160
| +5% | +$13.7M | 0.57% | 29 |
|
|
2023
Q4 | $305M | Buy |
3,764,107
+1,772,887
| +89% | +$138M | 0.66% | 23 |
|
|
2023
Q3 | $149M | Buy |
1,991,220
+812,043
| +69% | +$62.5M | 0.38% | 62 |
|
|
2023
Q2 | $90.9M | Buy |
1,179,177
+93,592
| +9% | +$7.46M | 0.21% | 101 |
|
|
2023
Q1 | $90.1M | Buy |
1,085,585
+96,077
| +10% | +$7.96M | 0.23% | 97 |
|
|
2022
Q4 | $84.9M | Sell |
989,508
-27,474
| -3% | -$2.18M | 0.23% | 95 |
|
|
2022
Q3 | $62.7M | Buy |
1,016,982
+248,263
| +32% | +$15.7M | 0.19% | 118 |
|
|
2022
Q2 | $47.5M | Sell |
768,719
-14,406
| -2% | -$892K | 0.15% | 141 |
|
|
2022
Q1 | $46.8M | Sell |
783,125
-221,920
| -22% | -$14.2M | 0.12% | 181 |
|
|
2021
Q4 | $73M | Buy |
1,005,045
+23,519
| +2% | +$1.62M | 0.16% | 138 |
|
|
2021
Q3 | $69.3M | Buy |
981,526
+17,960
| +2% | +$1.26M | 0.16% | 136 |
|
|
2021
Q2 | $66.4M | Buy |
963,566
+11,101
| +1% | +$741K | 0.15% | 142 |
|
|
2021
Q1 | $61.6M | Buy |
952,465
+138,050
| +17% | +$8.9M | 0.14% | 153 |
|
|
2020
Q4 | $47.4M | Buy |
814,415
+25,453
| +3% | +$1.54M | 0.12% | 156 |
|
|
2020
Q3 | $49.9M | Sell |
788,962
-74,896
| -9% | -$5.19M | 0.13% | 143 |
|
|
2020
Q2 | $66.5M | Sell |
863,858
-23,448
| -3% | -$1.8M | 0.18% | 113 |
|
|
2020
Q1 | $66.3M | Sell |
887,306
-33,370
| -4% | -$2.31M | 0.21% | 101 |
|
|
2019
Q4 | $59.8M | Sell |
920,676
-796
| -0.1% | -$51.8K | 0.14% | 126 |
|
|
2019
Q3 | $58.4M | Sell |
921,472
-418,663
| -31% | -$27.4M | 0.15% | 123 |
|
|
2019
Q2 | $90.5M | Buy |
1,340,135
+5,779
| +0.4% | +$380K | 0.2% | 96 |
|
|
2019
Q1 | $86.8M | Buy |
1,334,356
+23,848
| +2% | +$1.59M | 0.19% | 105 |
|
|
2018
Q4 | $82.6M | Sell |
1,310,508
-107,913
| -8% | -$7.54M | 0.2% | 104 |
|
|
2018
Q3 | $110M | Sell |
1,418,421
-195,561
| -12% | -$14.8M | 0.2% | 109 |
|
|
2018
Q2 | $114M | Sell |
1,613,982
-136,626
| -8% | -$9.65M | 0.22% | 103 |
|
|
2018
Q1 | $132M | Sell |
1,750,608
-183,129
| -9% | -$14.6M | 0.26% | 92 |
|
|
2017
Q4 | $139M | Sell |
1,933,737
-17,339
| -0.9% | -$1.32M | 0.27% | 94 |
|
|
2017
Q3 | $158M | Buy |
+1,951,076
| New | +$149M | 0.29% | 88 |
|
Other funds holding GILD
VCM
VPM
Aberdeen Group's GILD Position: Q1 2026 in Review
Aberdeen Group reduced its Gilead Sciences (GILD) stake by 7.2% in Q1 2026, selling an estimated $12M and leaving 1,100,253 shares worth $153M. The position accounts for 0.25% of the portfolio, ranked #79.
Aberdeen Group first reported a position in GILD in Q3 2017 and has held it in 35 quarters since. The position peaked at $346M in Q4 2024. 2,311 funds tracked by Wall St. Rank hold GILD as of Q1 2026.
- Aberdeen Group held 1,100,253 shares of Gilead Sciences worth $153M as of Q1 2026.
- Aberdeen Group sold 85,423 Gilead Sciences shares in Q1 2026, an estimated $12M.
- Gilead Sciences made up 0.25% of Aberdeen Group's portfolio in Q1 2026, its #79 holding.
- Aberdeen Group first reported a position in Gilead Sciences in Q3 2017 and has held it in 35 quarters since.
- Aberdeen Group's Gilead Sciences position peaked at $346M in Q4 2024.
- 2,311 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.
Based on Aberdeen Group's 13F filing for Q1 2026, filed 29 Apr 2026.